These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12071780)

  • 1. Signal generation in the New Zealand Intensive Medicines Monitoring Programme: a combined clinical and statistical approach.
    Coulter DM
    Drug Saf; 2002; 25(6):433-9. PubMed ID: 12071780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
    Clark DW; Harrison-Woolrych M
    Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated signal generation in prescription-event monitoring.
    Heeley E; Wilton LV; Shakir SA
    Drug Saf; 2002; 25(6):423-32. PubMed ID: 12071779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring data.
    Layton D; Heeley E; Shakir SA
    J Clin Pharm Ther; 2004 Apr; 29(2):171-81. PubMed ID: 15068407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2000 Jul; 9(4):273-80. PubMed ID: 19025828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 1998 Mar; 7(2):79-90. PubMed ID: 15073731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription-event monitoring in Japan (J-PEM).
    Kubota K
    Drug Saf; 2002; 25(6):441-4. PubMed ID: 12071781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative methods in pharmacovigilance: focus on signal detection.
    Hauben M; Zhou X
    Drug Saf; 2003; 26(3):159-86. PubMed ID: 12580646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records.
    Tomlin A; Reith D; Dovey S; Tilyard M
    Drug Saf; 2012 Sep; 35(9):733-43. PubMed ID: 22861670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena).
    Zhou L; Harrison-Woolrych M; Coulter DM
    Pharmacoepidemiol Drug Saf; 2003; 12(5):371-7. PubMed ID: 12899110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking pharmacovigilance with pharmacogenetics.
    Clark DW; Donnelly E; Coulter DM; Roberts RL; Kennedy MA
    Drug Saf; 2004; 27(15):1171-84. PubMed ID: 15588114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
    Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
    Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel statistical tools for monitoring the safety of marketed drugs.
    Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N
    Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
    Clark RC; Maxwell SR; Kerr S; Cuthbert M; Buchanan D; Steinke D; Webb DJ; Bateman ND
    Drug Saf; 2007; 30(4):357-66. PubMed ID: 17408312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prescription-event monitoring: developments in signal detection.
    Ferreira G
    Drug Saf; 2007; 30(7):639-41. PubMed ID: 17604421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.